PMcardio LVEF

Early Detection of Reduced LVEF on ECG with AI

PMcardio offers a rapid and accurate assessment of left ventricular (LV) systolic function. Utilizing advanced AI technology, it enables detection of reduced LVEF from a 12-lead ECG⁷.

Area under the curve (AUC)

Sensitivity

0 %

Specificity

0 %

The current standard of care

Understanding the Challenge

Accurate and timely assessment of left ventricular systolic function, measured by left ventricular ejection fraction (LVEF), is essential for optimal management and better patient outcomes¹.

Nonspecific Symptoms

Reduced LV systolic function often causes fatigue, dyspnoe, and edema, which can be mistaken for other health issues and delay diagnosis⁵.

Lack of Awareness

Patients and primary care providers often miss the risk factors and early symptoms of heart failure (HF), delaying care and appropriate diagnostic evaluations⁴.

Limited Echo Availability

Many healthcare settings lack advanced diagnostic tools and expertise, restricting patient access to quality care. Consequently, some cases of reduced LVEF go undetected in primary care, underestimating its true prevalence¹.

Heart Failure (HF) Overview

Prevalence:

Affects 1-2% of adults.
Over 10% prevalence in individuals aged 70 years or older (EU).
Expected to rise due to an aging population and improved survival rates (US)⁵.

Asymptomatic Reduced LVEF:

Affects 2.2-3.4% of the population (EU)³.

HF Hospitalizations:

1.2 million hospitalizations in 2017 (US)⁵.

Economic Impact:

Costs projected to increase from $30.7 billion in 2012 to $69.8 billion by 2030 (US)⁵.

Prognosis in Community Studies6:

1-year mortality rate: 20%.
5-year mortality rate: 53%-67%.

The current standard of care

The Role of Patient Screening

Routine screening using the AI-augmented 12-lead ECG allows for swift assessment of LV function. This helps to accurately identify patients needing confirmatory echocardiography7.

PMcardio Implementation

PMcardio offers a rapid and accurate assessment of left ventricular (LV) systolic function. Utilizing advanced AI technology, it enables detection of reduced LVEF from a 12-lead ECG⁷.

AI-Driven LVEF Assessment

The AI algorithm can assess LV systolic function on the ECG, a capability beyond many physicians' skills.

Enhancing Efficiency

Analyzing the ECG via AI algorithm significantly reduces the time required to assess LV function, enabling faster clinical decision-making and timely referral.

Improving Accessibility

We are committed to making advanced cardiac diagnostics accessible to a wider range of healthcare providers, ensuring more patients benefit from accurate LV systolic function assessment.

LVEF AI ECG Model

Impact of PMcardio

Timely Diagnosis

Enables earlier screening, helps differentiate underlying causes of symptoms, and allows for early lifestyle modifications and treatment².

Appropriate Treatment

Ensures more patients receive appropriate treatment based on guideline recommendations, increasing positive clinical outcomes³.

Reduced Hospitalizations

Early diagnosis and adequate treatment reduce acute exacerbations and complications of HF, minimizing hospitalizations³.

Cost Savings

Minimizes the need for advanced interventions and preventable hospitalizations, reducing overall healthcare expenditures.

Improved Patient Pathway

By identifying reduced LV systolic function early, we can create an improved patient pathway, ultimately reducing HF hospitalizations.

PMcardio's global presence

Global clinical evaluation of our AI-powered ECG interpretation platform PMcardio

Join more than 30 hospitals leveraging AI to streamline cardiac care and improve patient outcomes.

Be at the Forefront of Cardiac Care: Join the AI-driven LVEF Detection Revolution Today!

References:

Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015;16(3):233-70. https://doi.org/10.1093/ehjci/jev014.
Marwick TH, Gillebert TC, Aurigemma G, et al. Recommendations on the use of echocardiography in adult hypertension: a report from the European Association of Cardiovascular Imaging (EACVI) and the American Society of Echocardiography (ASE). Eur Heart J Cardiovasc Imaging. 2015;16(6):577-605. https://doi.org/10.1093/ehjci/jev076.
SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 Nov 19;327(10):685-91.
Ledwidge M, Gallagher J, Conlon C, Tallon E, O’Connell E, Dawkins I, Watson C, O’Hanlon R, Bermingham M, Patle A, Barry M, McDonald K. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013 Jul 3;310(1):66-74.
Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017 Oct;14(10):591-602. doi: 10.1038/nrcardio.2017.65. PMID: 28518150.
Benjamin EJ, Levy D, Vasan RS, D’Agostino RB, Belanger AJ, Wolf PA, et al. Impact of heart failure on mortality rates in the Framingham Heart Study population: an update. JAMA. 1999; 281(18):1728-34. doi:10.1001/jama.281.18.1728.
Demolder A, Herman R, Vavrik B, Martonak M, Boza V, Herman M, Palus T, Kresnakova V, Bahyl J, Iring A, Hatala R, Bartunek J, Vanderheyden M, Heggermont W, Penicka M. A smartphone-based AI model to detect left ventricular systolic dysfunction on 12-lead ECG. Abstract. Eur Heart J. In press.